Latest & greatest articles for methylphenidate

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on methylphenidate or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on methylphenidate and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for methylphenidate

22. Methylphenidate reduces ADHD symptoms in children with severe ADHD and intellectual disability

Methylphenidate reduces ADHD symptoms in children with severe ADHD and intellectual disability Methylphenidate reduces ADHD symptoms in children with severe ADHD and intellectual disability | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts (...) OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Methylphenidate reduces ADHD symptoms in children with severe ADHD and intellectual disability Article Text Children & Adolescents Methylphenidate reduces ADHD symptoms in children with severe ADHD

2013 Evidence-Based Mental Health

23. Effectiveness and safety of methylphenidate for ADHD in population between 6 and 19 years: a systematic review Full Text available with Trip Pro

Effectiveness and safety of methylphenidate for ADHD in population between 6 and 19 years: a systematic review Evaluaci�n de la efectividad y seguridad del metilfenidato para d�ficit atencional en poblaci�n entre 6 y 19 a�os: revisi�n sistem�tica - Medwave Revista Biom�dica Revisada Por Pares | | | | | Email: Clave: Medwave se preocupa por su privacidad y la seguridad de sus datos personales. Para poder enviarle a su direcci�n de correo electr�nico su contrase�a, es necesario que ingrese su e (...) -mail. Email: Revisi�n sistem�tica Medwave 2012 Sep;12(8):e5472 doi: 10.5867/medwave.2012.08.5472 Evaluaci�n de la efectividad y seguridad del metilfenidato para d�ficit atencional en poblaci�n entre 6 y 19 a�os: revisi�n sistem�tica Effectiveness and safety of methylphenidate for ADHD in population between 6 and 19 years: a systematic review Jos� Calleja, Jos� Uribarri | | Para Descargar PDF debe Abrir sesi�n. | | Palabras clave: attention deficit disorder with hyperactivity, methylphenidate

2012 Medwave

24. Effectiveness and safety of long-acting versus short acting methylphenidate in ADHD in population between 6 and 19 years: a systematic review Full Text available with Trip Pro

Effectiveness and safety of long-acting versus short acting methylphenidate in ADHD in population between 6 and 19 years: a systematic review Evaluaci�n de la efectividad y seguridad del metilfenidato de acci�n larga versus acci�n corta en el d�ficit atencional en poblaci�n entre 6 y 19 a�os: revisi�n sistem�tica - Medwave Revista Biom�dica Revisada Por Pares | | | | | Email: Clave: Medwave se preocupa por su privacidad y la seguridad de sus datos personales. Para poder enviarle a su direcci�n (...) de correo electr�nico su contrase�a, es necesario que ingrese su e-mail. Email: Revisi�n sistem�tica Medwave 2012 Sep;12(8):e5476 doi: 10.5867/medwave.2012.08.5476 Evaluaci�n de la efectividad y seguridad del metilfenidato de acci�n larga versus acci�n corta en el d�ficit atencional en poblaci�n entre 6 y 19 a�os: revisi�n sistem�tica Effectiveness and safety of long-acting versus short acting methylphenidate in ADHD in population between 6 and 19 years: a systematic review Jos� Calleja, Jos

2012 Medwave

25. Quillivant XR (methylphenidate hydrochloride) for Extended-Release Oral Suspension

Quillivant XR (methylphenidate hydrochloride) for Extended-Release Oral Suspension Drug Approval Package: QUILLIVANT XR (methylphenidate) NDA #202100 Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - QUILLIVANT XR (methylphenidate hydrochloride) for Extended-Release Oral Suspension 25 mg per 5 mL Company: NextWave Pharmaceuticals, Inc. Application No.: 202100 Approval Date: 09/27/2012 Persons with disabilities having problems accessing the PDF files below

2012 FDA - Drug Approval Package

26. [Efficacy of atomoxetine and methylphenidate in attention deficits hyperactivity disorder in adults: a rapid review]

[Efficacy of atomoxetine and methylphenidate in attention deficits hyperactivity disorder in adults: a rapid review] [Efficacy of atomoxetine and methylphenidate in attention deficits hyperactivity disorder in adults: a rapid review] [Efficacy of atomoxetine and methylphenidate in attention deficits hyperactivity disorder in adults: a rapid review] Jang BH, Lee HY, Jung YJ, An JH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA (...) . No evaluation of the quality of this assessment has been made for the HTA database. Citation Jang BH, Lee HY, Jung YJ, An JH. [Efficacy of atomoxetine and methylphenidate in attention deficits hyperactivity disorder in adults: a rapid review] Seoul: National Evidence-based Healthcare Collaborating Agency (NECA). NECA-C-12-007. 2012 Authors' conclusions The research was carried out using the basic existing systematic review framework suggested by the Agency for Healthcare Research and Quality (AHRQ 2009

2012 Health Technology Assessment (HTA) Database.

27. Review: methylphenidate and atomoxetine have similar efficacy and acceptability in children and adolescents with ADHD

Review: methylphenidate and atomoxetine have similar efficacy and acceptability in children and adolescents with ADHD Review: methylphenidate and atomoxetine have similar efficacy and acceptability in children and adolescents with ADHD | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your (...) username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: methylphenidate and atomoxetine have similar efficacy and acceptability in children and adolescents with ADHD Article Text Therapeutics Review

2012 Evidence-Based Mental Health

28. Comparative efficacy and acceptability of methylphenidate and atomoxetine in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis

Comparative efficacy and acceptability of methylphenidate and atomoxetine in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2011 DARE.

29. OROS methylphenidate (Concerta) for the treatment of children and adults with ADHD

and/or diversion of Concerta compared to other formulations of methylphenidate? Assessment principles: Included trials are double-blind randomized controlled trials (RCTs) in patients 6 years or older diagnosed with ADHD and comparing OROS formulation of methylphenidate to other long or short acting formulations of MPH or other standard therapy (amphetamine or atomoxetine) available in Canada. Methylphenidate formulations available in Canada are short-acting or “immediate-release” tablets: Ritalin (...) and the generics: PMS-methylphenidate and Apo-methylphenidate; sustained-release tablets: Ritalin SR; controlled-release capsules: Biphentin. Amphetamine preparations available in Canada are short-acting or “immediate-release” tablets: Dexedrine; sustained-release spansules: Dexedrine Spansule; and extended-release dextroamphetamine capsules: Adderall XR. Strattera (atomoxetine) is a long acting, non-stimulant. Therapeutic advantage will be assessed according to the following hierarchy of health outcomes – all

2010 Therapeutics Letter

30. Should a child with ADHD and epilepsy be given Ritalin?

. The Ovid Medline and EMBASE databases were also searched. MeSH words used were: ‘Methyphenidate’, ‘Epilepsy’, ‘Attention deficit disorder’. Keywords used were: ‘ADHD, attention deficit, attention deficit disorder’, ‘Epilepsy, seizure, fit’ and ‘Methylphenidate, Ritalin’. Limits were: English language and human. Search Outcome The Medline search revealed 13 results, of which three were potentially relevant. The EMBASE search revealed 34 results, of which six were potentially relevant. The remaining (...) Should a child with ADHD and epilepsy be given Ritalin? BestBets: Should a child with ADHD and epilepsy be given Ritalin? Should a child with ADHD and epilepsy be given Ritalin? Report By: Caroline Boyes - Specialist Registrar in Paediatrics Institution: General Paediatrics, Bradford Royal Infirmary, Bradford, West Yorkshire, UK Date Submitted: 28th October 2010 Date Completed: 28th October 2010 Last Modified: 28th October 2010 Status: Green (complete) Three Part Question In [a child

2010 BestBETS

31. Methylphenidate: new patient information

Methylphenidate: new patient information Methylphenidate: new patient information - GOV.UK GOV.UK uses cookies to make the site simpler. or Search Methylphenidate: new patient information The design and content of the Patient Information Leaflets for methylphenidate products are being updated with the latest guidance on safe and effective use for patients and carers Published 11 December 2014 From: Therapeutic area: , Contents Article date: January 2010 Methylphenidate is a stimulant treatment (...) for children aged 6 years or older and adolescents with attention-deficit hyperactivity disorder (ADHD). Patient information The design and content of the Patient Information Leaflets for methylphenidate products are being updated with the latest guidance on safe and effective use for patients and carers. This includes a tear-off section for children and adolescents who are taking methylphenidate. This tear-off section includes the most important messages written in an engaging style for children

2010 MHRA Drug Safety Update

32. Side effects of methylphenidate in childhood cancer survivors: a randomized placebo-controlled trial Full Text available with Trip Pro

Side effects of methylphenidate in childhood cancer survivors: a randomized placebo-controlled trial To investigate the frequency and severity of side effects of methylphenidate among childhood survivors of acute lymphoblastic leukemia and brain tumors and identify predictors of higher adverse effect levels.Childhood cancer survivors (N = 103) identified as having attention and learning problems completed a randomized, double-blind, 3-week, home-crossover trial of placebo, low-dose (...) methylphenidate (0.3 mg/kg; 10 mg twice daily maximum) and moderate-dose methylphenidate (0.6 mg/kg; 20 mg twice daily maximum). Caregivers completed the Barkley Side Effects Rating Scale (SERS) at baseline and each week during the medication trial. Siblings of cancer survivors (N = 49) were recruited as a healthy comparison group.There was a significantly higher number and severity of symptoms endorsed on the SERS when patients were taking moderate dose compared with placebo or low dose, but not low dose

2009 EvidenceUpdates Controlled trial quality: uncertain

33. A modelled economic evaluation comparing atomoxetine with methylphenidate in the treatment of children with attention-deficit/hyperactivity disorder in Spain Full Text available with Trip Pro

A modelled economic evaluation comparing atomoxetine with methylphenidate in the treatment of children with attention-deficit/hyperactivity disorder in Spain A modelled economic evaluation comparing atomoxetine with methylphenidate in the treatment of children with attention-deficit/hyperactivity disorder in Spain A modelled economic evaluation comparing atomoxetine with methylphenidate in the treatment of children with attention-deficit/hyperactivity disorder in Spain Hong J, Dilla T, Arellano (...) J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The aim was to evaluate the cost-effectiveness of atomoxetine compared with methylphenidate (immediate and extended release) or no treatment, in Spanish children with attention

2009 NHS Economic Evaluation Database.

34. Limits of meta-analysis: methylphenidate in the treatment of adult attention-deficit hyperactivity disorder

Limits of meta-analysis: methylphenidate in the treatment of adult attention-deficit hyperactivity disorder Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2009 DARE.

35. Attention deficit hyperactivity disorder in children: comparative efficacy of traditional Chinese medicine and methylphenidate

Attention deficit hyperactivity disorder in children: comparative efficacy of traditional Chinese medicine and methylphenidate Attention deficit hyperactivity disorder in children: comparative efficacy of traditional Chinese medicine and methylphenidate Attention deficit hyperactivity disorder in children: comparative efficacy of traditional Chinese medicine and methylphenidate Lan Y, Zhang LL, Luo R CRD summary This review identified trials of traditional Chinese medicine compared (...) with methylphenidate in children with attention deficit and hyperactivity disorder. The authors concluded that traditional Chinese medicine may be equal or superior to methylphenidate, but that more research was needed. Several methodological problems with the review may mean that the authors’ conclusions are not reliable. Authors' objectives To summarise existing evidence on the comparative effects of traditional Chinese medicine and methylphenidate for treating children with attention deficit and hyperactivity

2009 DARE.

36. Methylphenidate for the treatment of depressive symptoms, including fatigue and apathy, in medically ill older adults and terminally ill adults Full Text available with Trip Pro

Methylphenidate for the treatment of depressive symptoms, including fatigue and apathy, in medically ill older adults and terminally ill adults Methylphenidate for the treatment of depressive symptoms, including fatigue and apathy, in medically ill older adults and terminally ill adults Methylphenidate for the treatment of depressive symptoms, including fatigue and apathy, in medically ill older adults and terminally ill adults Hardy SE CRD summary The review did not find definitive evidence (...) of effectiveness of methylphenidate in medically ill older adults with depression, fatigue or apathy, although it appeared to be tolerated in the short term. Due to variation in outcomes, methodological flaws in the included studies and shortcomings in the review process, the reliability of the author's conclusions is not clear. Authors' objectives To assess the efficacy and tolerability of methylphenidate for the treatment of depressive symptoms, fatigue and apathy in medically ill older adults and adults

2009 DARE.

37. Review: Methylphenidate and psychosocial treatments either alone or in combination reduce ADHD symptoms

Review: Methylphenidate and psychosocial treatments either alone or in combination reduce ADHD symptoms Review: Methylphenidate and psychosocial treatments either alone or in combination reduce ADHD symptoms | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password (...) For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: Methylphenidate and psychosocial treatments either alone or in combination reduce ADHD symptoms Article Text Therapeutics Review: Methylphenidate and psychosocial

2009 Evidence-Based Mental Health

38. Osmotically released methylphenidate is more effective than atomoxetine in children and adolescents with ADHD

Osmotically released methylphenidate is more effective than atomoxetine in children and adolescents with ADHD Osmotically released methylphenidate is more effective than atomoxetine in children and adolescents with ADHD | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username (...) and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Osmotically released methylphenidate is more effective than atomoxetine in children and adolescents with ADHD Article Text Therapeutics Osmotically released

2009 Evidence-Based Mental Health

39. Varying the wear time of the methylphenidate transdermal system in children with attention-deficit/hyperactivity disorder (Abstract)

Varying the wear time of the methylphenidate transdermal system in children with attention-deficit/hyperactivity disorder Children with attention-deficit/hyperactivity disorder often have varying needs for coverage of their symptoms throughout the day. The objectives of this study were to determine the efficacy, duration of action, and safety of methylphenidate transdermal system worn for variable times by children (ages 6-12) diagnosed with ADHD.Methylphenidate dose was optimized over 5 weeks

2008 EvidenceUpdates Controlled trial quality: uncertain

40. Atomoxetine and Osmotically Released Methylphenidate for the Treatment of Attention Deficit Hyperactivity Disorder: Acute Comparison and Differential Response (Abstract)

Atomoxetine and Osmotically Released Methylphenidate for the Treatment of Attention Deficit Hyperactivity Disorder: Acute Comparison and Differential Response Response to atomoxetine, a nonstimulant norepinephrine-specific reuptake inhibitor, was compared with the effect of osmotic-release oral methylphenidate, a long-acting methylphenidate preparation, in patients with attention deficit hyperactivity disorder (ADHD).In a large placebo-controlled, double-blind study, patients ages 6-16 (...) with ADHD, any subtype, were randomly assigned to receive 0.8-1.8 mg/kg per day of atomoxetine (N=222), 18-54 mg/day of osmotically released methylphenidate (N=220), or placebo (N=74) for 6 weeks. The a priori specified primary analysis compared response (at least 40% decrease in ADHD Rating Scale total score) to osmotically released methylphenidate with response to atomoxetine and placebo. After 6 weeks, patients treated with methylphenidate were switched to atomoxetine under double-blind

2008 EvidenceUpdates Controlled trial quality: uncertain